Skip to main content

Skip to Investors Navigation

Pipeline

VMT-α-NET

Overview

VMT-α-NET is a clinical-stage radiopharmaceutical therapy for diagnosing and treating somatostatin receptor subtype 2 (SSTR2)-expressing neuroendocrine tumors (NETs). This radiopharmaceutical can be radiolabeled with Pb-203 for SPECT imaging and Pb-212 for alpha particle therapy.

203Pb SPECT Imaging Reveals Favorable VMT-α-NET Properties1

Rapid Tumor Targeting and Renal Clearance
High Tumor Retention
1Muller et al., Clin. Nucl. Med. 2023
  • Tumors visible within 1 hour indicates rapid binding to SSTR2 target
  • High intensity above background implies excellent therapeutic window
  • Unbound drug in bladder within 1 hour for excretion
  • Low renal retention due to neutral charge on proprietary Pb-specific chelator

Development

  • Ongoing multi-center Phase 1/2a dose-escalation/expansion trial (NCT05636618) in PRRT-naïve patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors, currently recruiting across the US
  • Updated interim data presented at the 2026 ASCO Gastrointestinal Cancers Symposium (data cut-off December 10, 2025) in 56 patients across three cohorts showed [212Pb]VMT-α-NET is well-tolerated with no dose-limiting toxicities, treatment-related discontinuations, or Grade 5 events; Grade ≥3 adverse events in 37.5% of patients (mostly manageable and non-renal/myelosuppressive)
  • In 25 evaluable patients (Cohorts 1 & 2) from the same interim analysis, 76% remained progression-free and alive; Cohort 2 showed 39% ORR per RECIST v1.1 (9/23 patients, with deepening responses), and 44% ORR / 87.5% progression-free in those with SSTR2+ in all lesions (median follow-up 41 weeks)
  • Cohort 3 (6.0 mCi) DLT assessment completed; enrollment continues for dose optimization; maximum tolerated dose not yet reached
  • Fast Track Designation granted by FDA (September 29, 2022) for SSTR2+ NETs regardless of prior treatment
  • Phase 1 study in PRRT-refractory patients (NCT06148636) recruiting at University of Iowa
  • Positioned for potential use in both PRRT-naïve and refractory settings, with further data updates and regulatory discussions planned for 2026